Pediatric Trial Plans Should Consider Drug Delivery Options, EC Says

Clinical Trials Advisor
When adding a pediatric indication to a drug product, drugmakers are advised to consider a range of different pharmaceutical forms and formulations that might be more suitable for children, a draft revision to European Commission guidelines on pediatric investigation plans says.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00